WuXi Biologics and Vertex have reached an agreement for licensing and research services on the innovative three specific T cell receptors.

On February 3rd, WuXi Biologics announced that it has signed an agreement with Vertex Pharmaceuticals for the authorization and research services of an innovative tri-specific T cell engager. Vertex plans to use this for the treatment of B cell-mediated autoimmune diseases. According to the terms of the agreement, Vertex will receive global exclusive development and commercialization rights for the tri-specific TCE, which is in the preclinical stage and planned for the treatment of B cell-mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and will be eligible for milestone payments related to development, registration, and sales, as well as sales royalties after the product is launched. In addition, WuXi Biologics will provide integrated contract research and development services for their innovative TCE.